Blood test may reveal hidden clues to hair loss severity

NCT ID NCT07733063

Recruiting now Knowledge-focused Sponsor: Istanbul Training and Research Hospital Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study investigates whether two substances in the blood—GPX4 and MDA—are linked to the severity of alopecia areata, a condition that causes patchy hair loss. Researchers will compare levels of these markers in 104 people with alopecia areata and 52 healthy volunteers. The goal is to see if these markers can serve as objective tools to monitor disease activity and hair loss progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If certain blood markers are linked to disease severity, doctors may have a simple way to monitor alopecia areata and guide treatment.
What could go wrong: This is an observational study, not a treatment trial. It may find no clear link between the markers and hair loss severity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA ALOPECIA AREATA ALOPECIA AREATA (& OPHIASIS) ALOPECIA AREATA(AA)

Contacts and locations

Locations

Istanbul Training and Research Hospital, Department of Dermatology
RECRUITING

Istanbul, Cerrahpasa Mahallesi, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.